



02-03-05

RCE 1632

PTO/SB/30 (09-04)

Request
for
Continued Examination (RCE)
Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/723,713
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1632
Examiner Name	Anne Marie Sabrina Wehbe
Attorney Docket Number	15270J-004741US

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☒ Consider the arguments in the Appeal Brief or Reply Brief previously filed on November 2, 2004
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☐ Amendment/Reply
- iii. ☒ Supp. IDS (6 pgs); PTO/SB/08A (2 pgs); PTO/SB/08B (6 pgs); copies of cited refs. 407-570, excluding US patent references
- ii. ☐ Affidavit(s)/ Declaration(s)
- iv. ☒ Other Pet. for Extension of Time (PTO/SB/22) (1p)

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 20-1430. I have enclosed a duplicate copy of this sheet.
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) | 02/07/2005 KBETEMA1 00000004 201430 09723713
- iii. ☐ Other 01 FC:1801 790.00 DA
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED


Signature	<i>Rosemarie L. Celli</i>	Date	February 1, 2005
Name (Print /Type)	Rosemarie L. Celli	Registration No.	42,397

CERTIFICATE OF MAILING OR TRANSMISSION

Express Mail Label: EV 530 892 013 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date February 1, 2005 and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature	<i>Marcel Wilson</i>	Date	February 1, 2005
Name (Print /Type)	MARCEL WILSON		



"Express Mail" Label No. EV 530 892 013 US

Date of Deposit 2/1/05

PATENT
Attorney Docket No.: 15270J-004741US
Client Reference No.: 209-US-CIP5C1

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Anne Marie Sabrina Wehbe

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the non US patent references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issue fee paid 07/28/04;
10/816,529 filed 03/31/04 issue fee paid 07/28/04;
10/815,391 filed 03/31/04 issue fee paid 07/28/04;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04;
10/933,559 filed 09/02/04;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04;
10/815,404 filed 03/31/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issue fee paid 07/28/04;
10/816,529 filed 03/31/04 issue fee paid 07/28/04;
10/815,391 filed 03/31/04 issue fee paid 07/28/04;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04;
10/933,559 filed 09/02/04;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04;
10/815,404 filed 03/31/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;

09/579,690 filed 05/26/00;

09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/04/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);

and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;

10/789,273 filed 2/27/04;

10/232,030 filed 08/30/02;

10/010,942 filed 12/6/01;

10/388,389 filed 03/12/03;

10/703,713 filed November 7, 2003;

10/704,070 filed November 7, 2003;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00;

60/137,010 filed 06/01/99;

60/251,892 filed 12/6/00;

60/137,047 filed 06/01/99;

60/136,655 filed 05/28/99; and

09/723,544 filed 11/28/00.

Applicant also cites the following abandoned applications directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;

60/474,654 filed 05/30/03;

60/530,481 filed 12/17/03;

60/444,150 filed 02/01/03; and,

60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00; and,


09/724,929 filed 11/28/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
60405615 v1



Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	1	of	8	Attorney Docket Number	15270J-004741US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	563	6,787,637	09-07-2004	Schenk et al.	
	562	6,750,324	06-15-2004	Schenk et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	516	6,261,569	07-17-2001	Comis et al.	
	452	6,218,506 B1	04-17-2001	Krafft et al.	
	510	6,022,859	02-08-2000	Kiessling, et al.	
	512	5,891,991	04-06-1999	Wasco et al.	
	445	5,854,215	12-29-1998	Findeis et al.	
	446	5,817,626	10-06-1998	Findeis et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	515	5,652,334	07-29-1997	Roberts	
	513	5,514,548	05-07-1996	Krebber et al.	
	514	5,470,951	11-28-1995	Roberts	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5,096,706	03-17-1992	Flint	
	570	4,912,206	03-27-1990	Goldgaber et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	2
-------	---

2

of

8

Application Number	09/723,713
--------------------	------------

09/723,713

Filing Date	November 27, 2000
-------------	-------------------

First Named Inventor	Schenk, Dale B.
----------------------	-----------------

Art Unit	1632
----------	------

Examiner Name	Anne Marie Sabrina Wehbe
---------------	--------------------------

Attorney Docket Number	15270J-004741US
------------------------	-----------------

[illegible]

Examiner
Signature

Date
Considered

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60405615 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	3	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).	
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001).	
	485	BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001).	
	504	BALBACH et al., "Amyloid fibril formation by A β ₁₈₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <i>Biochemistry</i> , 39:13748-13759 (2000).	
	550	BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <i>PNAS</i> , 100(4):2023-2028 (2003).	
	561	BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <i>Renal Failure</i> , 15(3):365-371 (1993).	
	558	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> , 268(23):26279-26285 (1993).	
	461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A4/ β amyloid peptide antigens," <i>J. Biol. Chem.</i> , 267:546-555 (1992).	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol. Chem.</i> , 276(24):21562-70 (2001).	
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <i>J. Mol. Biol.</i> , 186:651-663 (1985).	
	509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <i>J. Clin. Invest.</i> , 112:321-323 (2000).	
	462	CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <i>J. Immunol.</i> , 148:1149-1154 (1992).	
	541	CRIBBS et al, "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <i>J. Biol. Chem.</i> , 272:7431-7436 (1997).	
	469	DEMATTOIS et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , 98(15):8850-8855 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	4	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	493	DEMATTOS et al., "Plaque-associated disruption of CSF and plasma amyloid- β ($A\beta$) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-236 (2002).	
	486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).	
	475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998).	
	501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).	
	539	FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6791-6800 (1999).	
	464	FLOOD et al., "An amyloid β -Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures," <u>Brain Res</u> , 663(2):271-276 (1994).	
	538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).	
	565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem. J.</u> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J. Neurosci.</u> , 16 (19):6021-6037 (1996).	
	503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , 147(2):854-862 (1987).	
	487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?," <u>Nature Neuroscience</u> , 4(9):859-860 (2001).	
	476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> , 160:1029-1035 (1998).	
	559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979).	
	473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991).	
	471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	5	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).	
	546	IRIZARRY et al., " $A\beta$ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
	560	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).	
	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and $A\beta_{42}$ deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94:1550-1555 (1997).	
	547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999).	
	554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991).	
	488	KLEIN et al., "Targeting small $A\beta$ oligomers: the solution to an Alzheimer's disease conundrum?," <u>Trends in Neurosciences</u> , 24(4):219-224 (2001).	
	494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002).	
	465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. & Biophys. Res. Comm.</u> , 205:1164-1171 (1994).	
	478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999).	
	477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from $A\beta_{1-42}$ are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998).	
	489	LAMBERT et al., "Vaccination with soluble $A\beta$ oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 79:595-605 (2001).	
	490	LEE et al., " $A\beta$ immunization: Moving $A\beta$ peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001).	
	553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).	
	551	LEVERONE et al., " $A\beta_{1-15}$ is less immunogenic than $A\beta_{1-40/42}$ for intranasal immunization of wild-type mice but may be effective for 'boosting'," <u>Vaccine</u> , 21:2197-2206 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	6	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	459	LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983).	
	481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <u>American Neurological Assoc.</u> , 48:553-554 (2000).	
	499	LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-562 (1999).	
	502	MAGGIO et al., "Brain Amyloid – A Physicochemical Perspective," <u>Brain Pathology</u> , 6:147-162 (1996).	
	545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).	
	479	MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999).	
	482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <u>J. Am. Med. Assoc.</u> , 283:1571 (2000).	
	568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimmers," <u>PNAS</u> , 82:4592-4596 (1985).	
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856	
	491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001).	
	460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989).	
	497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998).	
	466	SCHWARZMAN et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994).	
	536	SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999).	
	552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).	
	505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	7	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	
	508	SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <u>J. Biol. Chem.</u> , 270(7):3063-3067 (1995).	
	496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993).	
	498	SUO et al., "Soluble Alzhemlers β -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998).	
	467	TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994).	
	472	TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996).	
	500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).	
	537	TJERNBERG, et al, "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <u>J. Biol. Chem.</u> , 272(19):12601-12605 (1997).	
	492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <u>Neurosci. Lett.</u> 307:101-104 (2001).	
	535	VAN REGENMORTEL et al, "D-peptides as immunogens and diagnostic reagents," <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998).	
	569	VERSHIGORA A. E. <u>OBSHCAYA IMMUNOLOGIYA</u> , pages 35, 229-231 and 152-153.	
	480	WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999).	
	495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002).	
	474	WINTER et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996).	
	468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol. Aging</u> , 15(2):143-52 (1994).	
	506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , 34:724-730 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	8	of	8	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity", <u>J. Exp. Med.</u> , 132:211-250 (1970).	
	507	XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997).	
	483	ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.